MedPath

Nicotine

Generic Name
Nicotine
Brand Names
Habitrol, Nicoderm C-Q, Nicorelief, Nicorette, Nicotrol
Drug Type
Small Molecule
Chemical Formula
C10H14N2
CAS Number
54-11-5
Unique Ingredient Identifier
6M3C89ZY6R
Background

Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke.

Indication

For the relief of nicotine withdrawal symptoms and as an aid to smoking cessation.

Associated Conditions
Withdrawal Nicotine
Associated Therapies
Smoking cessation therapy
Clinical Trials
Related News

4 mg Nicotine Polacrilex Gum and Swedish Portion Snus

Phase 1
Completed
Conditions
Healthy Subjects
Smokers
Interventions
Drug: Nicotine
First Posted Date
2010-08-16
Last Posted Date
2010-08-16
Lead Sponsor
Contract Research Organization el AB
Target Recruit Count
15
Registration Number
NCT01182129
Locations
🇸🇪

Carema AB, Eslov, Skane, Sweden

Pharmacokinetics With a New Oral Nicotine Replacement Product and Nicorette® Gum

Not Applicable
Completed
Conditions
Tobacco Dependence
Interventions
Drug: Nicotine
First Posted Date
2010-06-29
Last Posted Date
2012-07-10
Lead Sponsor
McNeil AB
Target Recruit Count
19
Registration Number
NCT01152736
Locations
🇸🇪

McNeil AB Clinical Pharmacology R&D, Lund, Sweden

Bioequivalence Between an Oral Nicotine Replacement Product and Nicorette® Gum

Not Applicable
Completed
Conditions
Tobacco Dependence
Interventions
Drug: Nicotine
Drug: Nicotine Gum
First Posted Date
2010-06-29
Last Posted Date
2012-07-10
Lead Sponsor
McNeil AB
Target Recruit Count
76
Registration Number
NCT01152749
Locations
🇸🇪

McNeil AB Clinical Pharmacology R&D, Lund, Sweden

Pharmacokinetics With Two New Oral Nicotine Replacement Products and Nicorette® Gum

Not Applicable
Completed
Conditions
Tobacco Dependence
Interventions
Drug: Nicotine
First Posted Date
2010-06-29
Last Posted Date
2012-07-10
Lead Sponsor
McNeil AB
Target Recruit Count
28
Registration Number
NCT01152723
Locations
🇸🇪

McNeil AB Clinical Pharmacology R&D, Lund, Sweden

Assessing Top Down and Bottom Up Attention Mechanisms in Smokers Using Nicotine Nasal Spray

Phase 1
Completed
Conditions
Drug Addiction
Nicotine Dependence
First Posted Date
2010-06-03
Last Posted Date
2019-12-16
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
43
Registration Number
NCT01136642
Locations
🇺🇸

National Institute on Drug Abuse, Biomedical Research Center (BRC), Baltimore, Maryland, United States

Bioequivalence Between Nicotine Replacement Products and Nicorette® Gum

Not Applicable
Completed
Conditions
Tobacco Dependence
Interventions
Drug: Nicotine
Drug: Nicorette® (Nicotine Gum)
First Posted Date
2010-04-29
Last Posted Date
2012-07-10
Lead Sponsor
McNeil AB
Target Recruit Count
88
Registration Number
NCT01113424
Locations
🇸🇪

Berzelius Clinical Research Center, Linköping, Sweden

Early Effects of a New Oral Nicotine Replacement Product and NiQuitin™ Lozenge

Phase 2
Completed
Conditions
Smoking Cessation
Interventions
Drug: Nicotine
First Posted Date
2010-02-25
Last Posted Date
2012-07-10
Lead Sponsor
McNeil AB
Target Recruit Count
200
Registration Number
NCT01075659
Locations
🇸🇪

Clinical Pharmacology, Lund, Sweden

Effects of Nicotine on Brain Opioid Receptors

Terminated
Conditions
Nicotine Dependence
Interventions
Drug: Nicotine
First Posted Date
2009-12-29
Last Posted Date
2019-04-11
Lead Sponsor
University of Pennsylvania
Target Recruit Count
15
Registration Number
NCT01040338
Locations
🇺🇸

Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Effects of Nicotine on Elements of Attentions in Smokers and Nonsmokers

Phase 1
Completed
Conditions
Substance Related Disorder
Nicotine Dependence
First Posted Date
2009-12-17
Last Posted Date
2017-07-02
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
100
Registration Number
NCT01034020
Locations
🇺🇸

National Institute on Drug Abuse, Biomedical Research Center (BRC), Baltimore, Maryland, United States

Efficacy and Safety Study of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Cessation

Phase 3
Completed
Conditions
Smoking
Interventions
Drug: Nicotine
Drug: Placebo
First Posted Date
2009-09-29
Last Posted Date
2014-06-27
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
723
Registration Number
NCT00985985
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy